Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: A double blind, randomized clinical trial of efficacy and safety

Critical Care

Volumn 17, Issue 5, 2013, Pages

  Kim, Ji Ho ^a   Shim, Jae Kwang ^b   Song, Jong Wook ^b   Song, Young ^b   Kim, Hye Bin ^b   Kwak, Young Lan ^c  

^a National Health Insurance Corporation   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Anesthesia and Pain Research Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYSTATIN C; EPOCAIN; INTERLEUKIN 6; MYELOPEROXIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; ANTIANEMIC AGENT; BIOLOGICAL MARKER; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; ADULT; AGED; ANESTHESIA INDUCTION; ARTICLE; CARDIOPULMONARY BYPASS; CASE CONTROL STUDY; CENTRAL VENOUS PRESSURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; HEART INDEX; HEART RATE; HEART VALVE SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RISK FACTOR; THROMBOEMBOLISM; ACUTE KIDNEY INJURY; BLOOD; HEART VALVE DISEASES; HEMATOCRIT; INCIDENCE; KIDNEY FUNCTION TEST; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; HEART VALVE DISEASES; HEMATINICS; HEMATOCRIT; HUMANS; INCIDENCE; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84886744969     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13081     Document Type: Article

References (40)

1. Mariscalco G, Lorusso R, Dominici C, Renzulli A, Sala A. Acute kidney injury: a relevant complication after cardiac surgery. Ann Thorac Surg 2011, 92:1539-1547. 10.1016/j.athoracsur.2011.04.123, 21872837.
2. Thakar CV, Yared JP, Worley S, Cotman K, Paganini EP. Renal dysfunction and serious infections after open-heart surgery. Kidney Int 2003, 64:239-246. 10.1046/j.1523-1755.2003.00040.x, 12787415.
3. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, Hiesmayr M. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol 2004, 15:1597-1605. 10.1097/01.ASN.0000130340.93930.DD, 15153571.
4. Conlon PJ, Stafford-Smith M, White WD, Newman MF, King S, Winn MP, Landolfo K. Acute renal failure following cardiac surgery. Nephrol Dial Transplant 1999, 14:1158-1162. 10.1093/ndt/14.5.1158, 10344355.
5. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 2006, 1:19-32. 10.2215/CJN.01420406, 17699187.
6. Kumar AB, Suneja M. Cardiopulmonary bypass-associated acute kidney injury. Anesthesiology 2011, 114:964-970. 10.1097/ALN.0b013e318210f86a, 21394005.
7. Tuttle KR, Worrall NK, Dahlstrom LR, Nandagopal R, Kausz AT, Davis CL. Predictors of ARF after cardiac surgical procedures. Am J Kidney Dis 2003, 41:76-83. 10.1053/ajkd.2003.50025, 12500223.
8. Katavetin P, Tungsanga K, Eiam-Ong S, Nangaku M. Antioxidative effects of erythropoietin. Kidney Int Suppl 2007, 107:S10-S15.
9. Moore E, Bellomo R. Erythropoietin (EPO) in acute kidney injury. Ann Intensive Care 2011, 1:3. 10.1186/2110-5820-1-3, 3159901, 21906325.
10. Shen Y, Wang Y, Li D, Wang C, Xu B, Dong G, Huang H, Jing H. Recombinant human erythropoietin pretreatment attenuates heart ischemia-reperfusion injury in rats by suppressing the systemic inflammatory response. Transplant Proc 2010, 42:1595-1597. 10.1016/j.transproceed.2009.11.050, 20620481.
11. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, Park KH, Han S, Kim JH, Na KY. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol 2009, 30:253-260. 10.1159/000223229, 19494484.
12. de Seigneux S, Ponte B, Weiss L, Pugin J, Romand JA, Martin PY, Saudan P. Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. BMC Nephrol 2012, 13:132. 10.1186/1471-2369-13-132, 3506492, 23033926.
13. Yoo YC, Shim JK, Kim JC, Jo YY, Lee JH, Kwak YL. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology 2011, 115:929-937. 10.1097/ALN.0b013e318232004b, 22027622.
14. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11:R31. 10.1186/cc5713, 2206446, 17331245.
15. Prabhu A, Sujatha DI, Ninan B, Vijayalakshmi MA. Neutrophil gelatinase associated lipocalin as a biomarker for acute kidney injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Ann Vasc Surg 2010, 24:525-531. 10.1016/j.avsg.2010.01.001, 20363104.
16. Tuladhar SM, Puntmann VO, Soni M, Punjabi PP, Bogle RG. Rapid detection of acute kidney injury by plasma and urinary neutrophil gelatinase-associated lipocalin after cardiopulmonary bypass. J Cardiovasc Pharm 2009, 53:261-266.
17. Arnaoutakis GJ, Bihorac A, Martin TD, Hess PJ, Klodell CT, Ejaz AA, Garvan C, Tribble CG, Beaver TM. RIFLE criteria for acute kidney injury in aortic arch surgery. J Thorac Cardiov Surg 2007, 134:1554-1560. discussion 1560-1551, 10.1016/j.jtcvs.2007.08.039, 18023682.
18. Janssen WM, Beekhuis H, de Bruin R, de Jong PE, de Zeeuw D. Noninvasive measurement of intrarenal blood flow distribution: kinetic model of renal 123I-hippuran handling. Am J Physiol 1995, 269:F571-F580.
19. Mehta RH, Grab JD, O'Brien SM, Bridges CR, Gammie JS, Haan CK, Ferguson TB, Peterson ED, . Society of Thoracic Surgeons National Cardiac Surgery Database Investigators Bedside tool for predicting the risk of postoperative dialysis in patients undergoing cardiac surgery. Circulation 2006, 114:2208-2216. quiz 2208, 10.1161/CIRCULATIONAHA.106.635573, 17088458, Society of Thoracic Surgeons National Cardiac Surgery Database Investigators.
20. Joyeux-Faure M. Cellular protection by erythropoietin: new therapeutic implications?. J Pharmacol Exp Ther 2007, 323:759-762. 10.1124/jpet.107.127357, 17717190.
21. Oh SW, Chin HJ, Chae DW, Na KY. Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting. J Korean Med Sci 2012, 27:506-511. 10.3346/jkms.2012.27.5.506, 3342541, 22563215.
22. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985, 28:830-838. 10.1038/ki.1985.205, 2418254.
23. Roos JF, Doust J, Tett SE, Kirkpatrick CM. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children-a meta-analysis. Clin Biochem 2007, 40:383-391. 10.1016/j.clinbiochem.2006.10.026, 17316593.
24. Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, Krawczeski CD, Koyner JL, Murray P, Zappitelli M, Goldstein SL, Makris K, Ronco C, Martensson J, Martling CR, Venge P, Siew E, Ware LB, Ikizler TA, Mertens PR. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol 2011, 57:1752-1761. 10.1016/j.jacc.2010.11.051, 21511111.
25. Loef BG, Epema AH, Smilde TD, Henning RH, Ebels T, Navis G, Stegeman CA. Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. J Am Soc Nephrol 2005, 16:195-200.
26. Poulsen TD, Andersen LW, Steinbruchel D, Gotze JP, Jorgensen OS, Olsen NV. Two large preoperative doses of erythropoietin do not reduce the systemic inflammatory response to cardiac surgery. J Cardiothorac Vasc Anesth 2009, 23:316-323. 10.1053/j.jvca.2008.08.018, 18948032.
27. Patel NS, Sharples EJ, Cuzzocrea S, Chatterjee PK, Britti D, Yaqoob MM, Thiemermann C. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 2004, 66:983-989. 10.1111/j.1523-1755.2004.00847.x, 15327391.
28. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003, 14:2199-2210. 10.1097/01.ASN.0000079785.13922.F6, 12874476.
29. McCluskey SA, Cheung WK, Katznelson R, Poonawala H, Fedorko L, Djaiani G, Mehta B, Karkouti K. The pharmacokinetic profile of recombinant human erythropoietin is unchanged in patients undergoing cardiac surgery. Eur J Clin Pharmacol 2009, 65:273-279. 10.1007/s00228-008-0575-6, 18972109.
30. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008, 264:405-432. 10.1111/j.1365-2796.2008.02024.x, 19017170.
31. Simon F, Scheuerle A, Calzia E, Bassi G, Oter S, Duy CN, Kick J, Bruckner UB, Radermacher P, Schelzig H. Erythropoietin during porcine aortic balloon occlusion-induced ischemia/reperfusion injury. Crit Care Med 2008, 36:2143-2150. 10.1097/CCM.0b013e31817d7912, 18552697.
32. Solling C, Christensen AT, Nygaard U, Krag S, Frokiaer J, Wogensen L, Krog J, Tonnesen EK. Erythropoietin does not attenuate renal dysfunction or inflammation in a porcine model of endotoxemia. Acta Anaesthiol Scand 2011, 55:411-421.
33. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, Barsness GW, Prather K, Heitner JF, Kilaru R, Gruberg L, Hasselblad V, Greenbaum AB, Patel M, Kim RJ, Talan M, Ferrucci L, Longo DL, Lakatta EG, Harrington RA. REVEAL Investigators: Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 2011, 305:1863-1872. 10.1001/jama.2011.592, 3486644, 21558517.
34. Hojman P, Taudorf S, Lundby C, Pedersen BK. Erythropoietin augments the cytokine response to acute endotoxin-induced inflammation in humans. Cytokine 2009, 45:154-157. 10.1016/j.cyto.2008.12.005, 19167238.
35. Ghaboura N, Tamareille S, Ducluzeau PH, Grimaud L, Loufrani L, Croue A, Tourmen Y, Henrion D, Furber A, Prunier F. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3beta signaling. Basic Res Cardiol 2011, 106:147-162. 10.1007/s00395-010-0130-3, 20981553.
36. Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes 2007, 56:127-136. 10.2337/db06-0907, 17192474.
37. Tanaka K, Kehl F, Gu W, Krolikowski JG, Pagel PS, Warltier DC, Kersten JR. Isoflurane-induced preconditioning is attenuated by diabetes. Am J Physiol Heart Circ Physiol 2002, 282:H2018-H2023.
38. Kim HS, Cho JE, Hwang KC, Shim YH, Lee JH, Kwak YL. Diabetes mellitus mitigates cardioprotective effects of remifentanil preconditioning in ischemia-reperfused rat heart in association with anti-apoptotic pathways of survival. Eur J Pharmacol 2010, 628:132-139. 10.1016/j.ejphar.2009.11.032, 19944681.
39. Jensen RV, Stottrup NB, Kristiansen SB, Botker HE. Release of a humoral circulating cardioprotective factor by remote ischemic preconditioning is dependent on preserved neural pathways in diabetic patients. Basic Res Cardiol 2012, 107:285.
40. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA, . CHEST Investigators, Australian and New Zealand Intensive Care Society Clinical Trials Group Hydroxyethyl starch or saline for fluid resuscitation in intensive care. New Engl J Med 2012, 367:1901-1911. 10.1056/NEJMoa1209759, 23075127, CHEST Investigators, Australian and New Zealand Intensive Care Society Clinical Trials Group.